靶向治疗HER2阳性乳腺癌患者的新型抗体药物偶联物:T-DM1与T-DXd  

A new type of antibody drug conjugate targeting HER2 therapy for breast cancer:T-DM1 and T-DXd

作　　者：何明星 张露 谭燕 HE Ming-xing;ZHANG Lu;TAN Yan(Department of Pharmacy,Tongnan People’s Hospital,Chongqing 402660;Department of Pharmacy,Dianjiang People’s Hospital,Chongqing 408300;Department of Oncology,Dianjiang People’s Hospital,Chongqing 408300)

机构地区：[1]重庆市潼南区人民医院药剂科,重庆402660 [2]重庆市垫江县人民医院药剂科,重庆408300 [3]重庆市垫江县人民医院肿瘤科,重庆408300

出　　处：《中南药学》2024年第7期1877-1882,共6页Central South Pharmacy

摘　　要：抗体药物偶联物是一类很有前景的药物,它利用单克隆抗体的特异性,选择性地将所连接的细胞毒类药物递送至肿瘤细胞内,通过增加抗肿瘤活性和降低脱靶毒性来达到更好的治疗效果。随着肿瘤精准治疗时代的到来,恩美曲妥珠单抗(T-DM1)与德曲妥珠单抗(T-DXd)为HER2阳性乳腺癌患者带来了巨大希望,也开启了HER2过表达及低表达乳腺癌患者治疗的新征程。本文就这两种药物的作用机制、适应证、有效性及安全性等方面进行论述,对临床合理使用提供参考。Antibody drug conjugate is a promising class of drugs that utilize the specificity of monoclonal antibodies to selectively deliver the attached cytotoxic small molecules to the inside of tumor cells,achieving better results by increasing anti-tumor activity and decreasing off-target toxicity.With the advent of the era of precision tumor therapy,trastuzumab emtansine(T-DM1)and trastuzumab deruxtecan(T-DXd)have brought great hope for patients with human epidermal growth factor receptor 2 positive breast cancer,opening up a new phase in the treatment of HER2 overexpressing breast cancer and even some HER2 low-expressing breast cancer.This review discussed the mechanism of action,indication,efficacy and safety of T-DM1 and T-DXd,which may have an important guiding role for rational drug use.

关 键 词：恩美曲妥珠单抗 德曲妥珠单抗 抗体药物偶联物 HER2 乳腺癌 

分 类 号：R730.5[医药卫生—肿瘤]